A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia

PCR protocols — A guide to methods and applications

1990 • 12,897 citations

PCR protocols — A guide to methods and applications

1990 • 10,078 citations

Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer

2003 • 6,072 citations

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53

1990 • 3,896 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

2004 • 1,624 citations

A Controlled Trial of a Human Papillomavirus Type 16 Vaccine

2002 • 1,570 citations

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

2005 • 1,551 citations

The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes

1989 • 1,345 citations

Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product.

1989 • 1,186 citations

Improved Amplification of Genital Human Papillomaviruses

2000 • 1,137 citations

A Cohort Study of the Risk of Cervical Intraepithelial Neoplasia Grade 2 or 3 in Relation to Papillomavirus Infection

1992 • 952 citations

Heat shock proteins and the immune response

1990 • 944 citations

Effective screening programmes for cervical cancer in low- and middle-income developing countries.

2001 • 721 citations

Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations

1997 • 699 citations

Heat shock protein 70-associated peptides elicit specific cancer immunity.

1993 • 631 citations

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

2006 • 452 citations

Natural history of cervical squamous intraepithelial lesions: a meta-analysis*1

1998 • 430 citations

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

2002 • 387 citations

Epidemiologic Profile of Type‐Specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica

2005 • 377 citations

DETECTION AND TYPING OF GENITAL HUMAN PAPILLOMAVIRUSES

1990 • 318 citations

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

2000 • 314 citations

Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

2004 • 311 citations

Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway

1997 • 253 citations

Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: A pilot study

2000 • 250 citations

Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.

2003 • 242 citations

Mechanisms Used by Human Papillomaviruses to Escape the Host Immune Response

2007 • 240 citations

Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras.

1989 • 227 citations

Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.

2002 • 225 citations

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

2002 • 196 citations

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX? adjuvant in women with cervical intraepithelial neoplasia

2004 • 178 citations

Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.

1998 • 176 citations

Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprisingMycobacterium bovisbacille Calmette–Guérin (BCG) hsp65 and HPV16 E7

2000 • 176 citations

Treatment of cervical intraepithelial neoplasia using the loop electrosurgical excision procedure.

1992 • 173 citations

Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.

2003 • 168 citations

Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA

2003 • 147 citations

Natural T-helper immunity against human papillomavirus type 16 (hpv16) e7-derived peptide epitopes in patients with hpv16-positive cervical lesions: Identification of 3 human leukocyte antigen class ii-restricted epitopes

2001 • 145 citations

Therapeutic Vaccination with MVA E2 Can Eliminate Precancerous Lesions (CIN 1, CIN 2, and CIN 3) Associated with Infection by Oncogenic Human Papillomavirus

2004 • 134 citations

Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.

2002 • 129 citations

Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination

2004 • 127 citations

Therapeutic cancer vaccines

2006 • 121 citations

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)

2004 • 113 citations

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein?based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

2004 • 110 citations

Cancer in women

2003 • 108 citations

T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia

2005 • 85 citations

Alum with Interleukin-12 Augments Immunity to a Melanoma Peptide Vaccine: Correlation with Time to Relapse in Patients with Resected High-Risk Disease

2007 • 81 citations

Human Papillomavirus Can Escape Immune Recognition through Langerhans Cell Phosphoinositide 3-Kinase Activation

2005 • 81 citations

Predicted highly expressed genes in archaeal genomes

2005 • 57 citations

Human papillomavirus type 6 in squamous cell carcinoma of the bladder and cervix

1993 • 49 citations

Immune Responses to a Class II Helper Peptide Epitope in Patients with Stage III/IV Resected Melanoma

2004 • 47 citations

Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study

2005 • 42 citations

Disease-Stage Variance in Functional CD4+ T-Cell Responses Against Novel Pan-Human Leukocyte Antigen-D Region Presented Human Papillomavirus-16 E7 Epitopes

2004 • 33 citations

Human papillomavirus-specific viral types are common in Mexican women affected by cervical lesions

2006 • 31 citations

Comparison of the Polymerase Chain Reaction and Southern Blot Analysis in Detecting and Typing Human Papilloma Virus Deoxyribonucleic Acid in Tumors of the Lower Female Genital Tract

1994 • 25 citations

CoVal fusions: a therapeutic vaccine platform using heat shock proteins to treat chronic viral infection and cancer.

2004 • 2 citations